These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 15943841)

  • 1. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
    Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
    Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
    Bergman MP; Klinkenberg-Knol EC; Faller G; Aar A; Lakhai W; Vandenbroucke-Grauls CM; Kuipers EJ; Appelmelk BJ
    Aliment Pharmacol Ther; 2005 Apr; 21(8):977-83. PubMed ID: 15813833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
    Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
    Rauws EA
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):569-73. PubMed ID: 9513835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia.
    Vakil N; Talley NJ; Stolte M; Sundin M; Junghard O; Bolling-Sternevald E
    Aliment Pharmacol Ther; 2006 Jul; 24(1):55-63. PubMed ID: 16803603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
    Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
    Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
    Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carditis: all Helicobacter pylori or is there a role for gastro-oesophageal reflux?
    McNamara D; Buckley M; Crotty P; Hall W; O'Sullivan M; O'Morain C
    Scand J Gastroenterol; 2002 Jul; 37(7):772-7. PubMed ID: 12190089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
    Lundell L; Havu N; Miettinen P; Myrvold HE; Wallin L; Julkunen R; Levander K; Hatlebakk JG; Liedman B; Lamm M; Malm A; Walan A;
    Aliment Pharmacol Ther; 2006 Mar; 23(5):639-47. PubMed ID: 16480403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
    Delaney B; McColl K
    Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
    Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L
    Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.